Prevalence of Antibodies to the Core Protein P17,<i>a</i>Serological Marker During HIV-1 Infection

Mehta, Smriti U.; Rupprecht, Kevin; Hunt, Jeffrey C.; Kramer, Debra; McRae, B J; Allen, Rhonda G.; Dawson, George J.; Devare, Sushil G.

doi:10.1089/aid.1990.6.443

Cited by 21 publications

(5 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…sera [10,11,13]; however, a single time-point measurement per patienl cannot adequately represent the humoral response to pi7. A longitudinal approach provides a more powerful analysis, as recently shown for the antibody response to HIV-l p24 [9].…”

Section: Discussionmentioning

confidence: 99%

A longitudinal study of the IgG antibody response to HIV-1 pl7gagprotein in HIV-1+ patients with haemophilia: titre and avidity

Chargelegue

O’Toole

Colvin

1993

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SUMMARYThe IgG response to HIV-I pl7 gag protein was studied for up to 6 years in 12 HIV-1-infected patients with haemophilia, who had seroconverted between 1982 and 1985. To assess any prognostic value, pi 7 IgG titres were compared with p24 IgG titrcs. CD4 cell counts and p24antigenaemia. pi7 IgG avidity index was also examined. A strong similarity was found between the IgG titre to HlV-l pl7 and that to p24. In patients who developed AIDS the decline inpl7 IgG titres could precede by several years the drop in CD4 cells to under 200 cclls//il: whereas some long-term asymptomatic patients (CDCII) had increasing pl7 IgG titres and stable CD4 cell counts. Declining pl7 and p24 IgG titres were not always associated with an increase in p24 antigenaemia. IgG titres were found to be better predictors of di.sease progression than CD4 eell counts or p24 antigenaemia. Patients who developed AIDS during the study were also characterized by a lower pl7 IgG avidity than patients who remained asymptomatic . This result suggests that IgG avidity could have prognostic relevance and be of importance for host resistance to AIDS onsetKeywords lUV-i gag antibody response p24 antigenaemia avidity prognostic markers INTRODUCTION

show abstract

Section: Discussionmentioning

confidence: 99%

A longitudinal study of the IgG antibody response to HIV-1 pl7gagprotein in HIV-1+ patients with haemophilia: titre and avidity

Chargelegue

O’Toole

Colvin

1993

Clinical and Experimental Immunology

View full text Add to dashboard Cite

show abstract

“…In the former case, anti-p 17 antibody is a surrogate marker for the onset of disease but in the latter, it has a role of protective antibody. Although both anti-p 17 and anti-p24 have been considered to be disease markers (13,15), they differ markedly in their character (16,19). In vitro studies support the fact that, unlike anti-p24, anti-p 17 antibody has neutralizing activity against HIV.…”

Section: Discussionmentioning

confidence: 98%

“…Absence or reduction of anti-p24 antibodies are shown to be related with rapid progression to AIDS (22). Recent evidence suggests functional differences between the nature of two antibodies (16,19). Sarin et al had showed that thymosin alpha-1 and gag proteins (p17) of HTLV-III/LAV (clone BH-10) are 44-50% homologous in an 18-amino acid region (positions 11-28 on thymosin alpha-1 and 92-109 on the p17 position) of their primary sequences (21).…”

mentioning

confidence: 99%

A Prospective Study on Correlation between the Decrease in Anti‐P17 Antibody Level and Progression to AIDS in Asymptomatic Carriers of HIV

Choudhury¹,

Wakamiya²,

Kurimura³

1992

Microbiology and Immunology

View full text Add to dashboard Cite

As the majority of human immunodeficiency virus (HIV) carriers are in asymptomatic stage for a long period of time, it is important to investigate the factors or surrogate markers for conversion from asymptomatic to symptomatic stage. Our study is designed to evaluate the relationship among virus isolation rate, anti-p17 antibody status and progression to AIDS. We studied anti-p17 antibody status along with virus isolation in 56 asymptomatic carriers and 46 AIDS cases. Progression to AIDS was markedly associated with high rate of virus isolation and loss of anti-p17 antibody. In order to know the meaning of loss of anti-p17 antibody during the clinical course, 15 anti-p17 antibody positive and 16 anti-p17 antibody negative cases were followed up prospectively for the development of AIDS. None of the anti-p17 antibody positive cases developed AIDS while 6 out of 16 anti-p 17 negative cases developed AIDS during observation period (P< 0.05). Progression to AIDS was associated with loss of anti-p17 antibody. Identification of cases losing anti-p 17 antibody in peripheral blood during asymptomatic period may help high-risk group who are in need of chemoprophylaxis. Moreover, study of anti-p17 antibody may be helpful in designing vaccine in future if it works as a neutralizing antibody to HIV in vivo.

show abstract

“…nef [62], or may act as prognostic indicators, e.g. pl7 [57,59], nef [62] or RT [59,60]. In addition, loss of p24 antibodies in the later stages of disease is associated with transition to AIDS [56,99], the higher affinity antibodies being preferentially bound into immune complexes [100].…”

Section: Serum Antibodies To Hivmentioning

confidence: 99%

B cell responses to HIV and the development of human monoclonal antibodies

Boyd

James

1992

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SUMMARYIn this review B cell responses in HIV-infected individuals are summarized together with the techniques used to date to produce human monoclonals to HIV and the properties of these antibodies. Profound disturbances in B cell responses are apparent both in vivo and in vitro. While there is evidence in vivo of marked polyclonal B cell activation, primary and secondary antibody responses are impaired. Similarly these cells exhibit spontaneous immunoglobulin secretion upon in vitro culture but do not readily respond to B cell mitogens and recall antigens including HIV. Furthermore, certain of these defects can be reproduced in normal B cells in vitro by incubation with HIV or HIV coded peptides. Individuals infected with HIV develop antibodies to HIV structural proteins (e.g. pl7, p24, gp41 and gpl20) and regulatory proteins (e.g. vif, nef, RT). Autoantibodies against a number of immunologically important molecules are also frequently observed. The anti-HIV antibodies are predominantly ofthe IgGl isotype and exhibit a variety of effects on the virus in vitro. To date, using conventional immortalization strategies, an appreciable number of human monoclonals to HIV have been developed. These have been specific for gp41, gpl20 and gag with antibodies ofthe former specificity predominating. The majority of these antibodies have been ofthe IgGl isotype. Only a small number ofthe antibodies neutralize virus in vitro and most of these react with gpl20. The neutralizing antibodies recognize conformational and carbohydrate epitopes or epitopes in amino acid positions 306-322. The predominant epitopes recognized by the anti-gp41 antibodies were in amino acid positions 579-620 and 644-662. A high percentage (=^ 25%) of these antibodies enhance viral growth in vitro. The problems relating to the production of human monoclonals to HIV are discussed together with strategies that could be used in the future.

show abstract

Prevalence of Antibodies to the Core Protein P17,aSerological Marker During HIV-1 Infection

Cited by 21 publications

References 26 publications

A longitudinal study of the IgG antibody response to HIV-1 pl7gagprotein in HIV-1+ patients with haemophilia: titre and avidity

A longitudinal study of the IgG antibody response to HIV-1 pl7gagprotein in HIV-1+ patients with haemophilia: titre and avidity

A Prospective Study on Correlation between the Decrease in Anti‐P17 Antibody Level and Progression to AIDS in Asymptomatic Carriers of HIV

B cell responses to HIV and the development of human monoclonal antibodies

Contact Info

Product

Resources

About